Royalty Report: Drugs, Disease, Pharmaceuticals – Collection: 6583

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Disease
  • Pharmaceuticals
  • Therapeutic
  • Pain
  • Gastrointestinal

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6583

License Grant
In April 2009, the Licensor entered into a license agreement with the Spanish Licensee to develop and commercialize linaclotide in Europe (including the Commonwealth of Independent States countries and Turkey) for the treatment of IBS-C and other gastrointestinal conditions. The Licensee is responsible for activities and expenses relating to regulatory approval and commercialization in the European market.
Field of Use
Linaclotide is a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause. It has a black box warning about the risk of serious dehydration in children in the US; the most common adverse effects in others are gastrointestinal.

IPSCIO Record ID: 6566

License Grant
The Licensor entered into a partnership with the Licensee, to co-develop and co-market linaclotide in the U.S. Under the terms of the collaboration Agreement, the Licensor and the Licensee are jointly and equally funding the development and commercialization of linaclotide in the U.S., with equal share of any profits. The Licensee also has exclusive rights to develop and commercialize linaclotide in Canada and Mexico. The collaboration Agreement will continue in full force and effect with respect to each of the U.S., Canada and Mexico as long as the parties are developing or commercializing a product under the Agreement.
License Property
Phase 3 drug candidate (linaclotide), is a first-in-class compound currently in confirmatory Phase 3 clinical trials evaluating its safety and efficacy for the treatment of patients with irritable bowel syndrome with constipation (IBS-C) or chronic constipation (CC). Linaclotide recently achieved favorable efficacy and safety results in two Phase 3 CC trials, meeting all 32 primary and secondary endpoints, including the improvement of abdominal symptoms such as bloating and discomfort as well as constipation symptoms, across both doses evaluated in these independent trials involving 1,287 subjects.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 281377

License Grant
Under the terms of the amended agreement, Licensee will obtain exclusive rights to develop, manufacture and commercialize linaclotide in China (including Hong Kong and Macau) and will be responsible for all expenses associated with these activities.  This amendment also includes for the development and commercialization of LINZESS in China.
License Property
LINZESS (linaclotide) is indicated in adults for the treatment of both irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).  LINZESS was approved by the National Medical Products Administration for adults with IBS-C in China.

Linaclotide is available for the treatment of adults with IBS-C or chronic idiopathic constipation (CIC).  Linaclotide is a guanylate cyclase-C (GC-C) agonist that is thought to work in two ways based on nonclinical studies. Linaclotide binds to the GC-C receptor locally, within the intestinal epithelium. Activation of GC-C results in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine.

Licensor is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 6538

License Grant
The Licensor entered into a partnership with the Licensee, to co-develop and co-market linaclotide in the U.S.  Under the terms of the collaboration Agreement, the Licensor and the Licensee are jointly and equally funding the development and commercialization of linaclotide in the U.S., with equal share of any profits. The Licensee also has exclusive rights to develop and commercialize linaclotide in Canada and Mexico. The collaboration Agreement will continue in full force and effect with respect to each of the U.S., Canada and Mexico as long as the parties are developing or commercializing a product under the Agreement.
License Property
Linaclotide is a first-in-class compound currently in confirmatory Phase 3 clinical trials evaluating its safety and efficacy for the treatment of patients with irritable bowel syndrome with constipation (IBS-C) or chronic constipation (CC).
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 4001

License Grant
The Licensor entered into a License Agreement with the Licensee to develop and commercialize linaclotide for the treatment of IBS-C and other gastrointestinal conditions.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 4065

License Grant
The UK Licensor entered into a collaboration and license agreement with a Japanese Licensee to jointly develop and commercialize Amitiza for CIC and IBS-C and other gastrointestinal indications in the U.S. and Canada.

The key terms of agreements are that the Licensee commercializes and markets Amitiza for GI indications in U.S. and Canada.

The agreement currently covers two indications CIC in adults and IBS-C in adult women.  The Licensor holds right of first refusal to additional GI indications.  The Licensee records all U.S. sales.

License Property
Amitiza® First FDA approved drug for chronic idiopathic constipation (CIC) in adults of all ages (Amitiza 24 mcg) Only FDA approved drug for irritable bowel syndrome with constipation (IBS-C) in women 18 years and older (Amitiza 8 mcg).
Field of Use
Currently covers two indications CIC in adults and IBS-C in adult women.  The Company holds right of first refusal to additional GI indications.

IPSCIO Record ID: 269165

License Grant
The Irish Company licenses certain rights to Amitiza to an undisclosed third party in exchange for royalties on net sales of the product.
License Property
Amitiza includes niche specialty generic drugs products, active pharmaceutical ingredients ('API(s)') and Amitiza® (lubiprostone) ('Amitiza').

Licensor develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics.

Field of Use
Amitiza is medication used to treat certain types of constipation (chronic idiopathic constipation, irritable bowel syndrome with constipation). Chronic idiopathic constipation has an unknown cause and is not due to diet, other diseases, or drugs.

IPSCIO Record ID: 2810

License Grant
Licensor grants an exclusive license to make, have made, use or sell for use in the Field within the United States and its territories (Puerto Rico, Guam), Canada and Mexico.  The Compound and Product pursuant to all Licensor’s Intellectual Property Rights.
License Property
Licensor has discovered a compound internally designated as LY315535 (5,434,174) which may be useful in the treatment of functional gastrointestinal disorders and other indications.

Compound means 2-di-n-propylamino-8-(isoxazol-5-yl)-1,2,3,4-tetrahydronaphthalene and all pharmaceutically acceptable salts and solvates.

Field of Use
Field means products for Gastrointestinal Indications.  
Gastrointestinal Indications means disease states, such as excess gastric acid secretion, inflammatory bowel disease, irritable bowel syndrome, gastroesophagael reflux disease, esophagitis, dyspepsia, proctitis, hemorrhoids, gastrointestinal ulceration, nausea and vomiting and constipation and diarrhea, which are characterized by abnormalities of the Digestive System, regardless of the mechanism involved in such disease states.

IPSCIO Record ID: 2796

License Grant
The Licensor's lead product is Relistorâ„¢ (methylnaltrexone bromide).
License Property
On April 24, 2008, Relistor subcutaneous injection was approved by the U.S. Food and Drug Administration for sale in the United States for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Our collaboration partner, the Licensee, commenced sales of Relistor subcutaneous injection in the U.S. in June 2008.
Field of Use
Opioid-induced constipation (OIC) often occurs in patients administered opioids for chronic noncancer pain. Patients commonly experience hard, infrequent, and incomplete bowel movements with bloating and straining, which may impact pain management and quality of life.  Opioid-induced constipation is attributed to activation of enteric µ-opioid receptors, which decrease bowel tone and contractility and increase colonic fluid absorption and anal sphincter tone while reducing rectal sensation. This leads to harder stools, which can be difficult to pass.

IPSCIO Record ID: 26279

License Grant
The Licensor entered into a collaboration Agreement with the Licensee for the exclusive worldwide development and commercialization of Entereg for certain indications. The Licensor is responsible for the development of acute indications, such as postoperative ileus, and the Licensee is responsible for the development of chronic indications, such as opioid bowel dysfunction. In the United States, the Licensee and the Licensor are co-developing Entereg and intend to share profits or losses that result from the sale of the product.
License Property
Entereg is a drug which behaves as a peripherally acting µ-opioid antagonist. With limited ability to cross the blood–brain barrier, many of the undesirable side-effects of the opioid agonists such as constipation are minimized without affecting analgesia or precipitating withdrawal.

Opioid analgesics provide pain relief by stimulating opioid receptors located in the central nervous system. There are, however, opioid receptors throughout the body, including the GI tract. By binding to the receptors in the GI tract, opioid analgesics can slow gut motility and disrupt normal GI function that allows for the passage, absorption and excretion of ingested solid materials. This disruption can cause patients to experience significant discomfort and abdominal pain and may result in their reducing or eliminating their pain medication.
Entereg is a small molecule, mu-opioid receptor antagonist intended to block the adverse side effects of opioid analgesics on the GI tract without affecting analgesia. We are developing Entereg for both acute and chronic conditions.

Licensor is currently developing a compound known as alvimopan for postoperative bowel dysfunction and other gastrointestinal disorders.  Alvimopan is indicated for the management of postoperative ileus or management of post operative bowel dysfunction in open laparotomies except simple hysterectomies.

Product means a prescription pharmaceutical product that contains Compound as the sole active ingredient for use in the Field. For the avoidance of doubt, Product shall not include products sold in the OTC market.

Licensor Products means a POI Product, an OBD Acute Product or any Additional Product designated by the Parties as an Licensor Product.

Additional Product means a PONV Product and any Product other than a POI Product, an OBD Acute Product, an OBD Chronic Product, a Constipation Product or an IBS Product included by the Parties.

Licensor Housemark means the name and logo of Licensor.

Collaboration Products means the Licensor Products and the GI Products.

Compound means the peripheral mu antagonist having molecular formula(+)-[[2(S)-[[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-1-piperidinyl]- methyl]-1-oxo-3-phenylpropyl]amino]acetic acid dihydrate, known generically as 'alvimopan', and all pharmaceutically acceptable salts and solvates thereof.

Constipation Product means a Product for the management of non-opioid induced forms of constipation or bowel dysfunction which such Product is not an IBS Product.

GI Product means an OBD Chronic Product, a Constipation Product, an IBS Product, or any Additional Product designated by the Parties as a GI Product.

POI Product means a Product for the prevention, treatment or management of post-operative ileus or post-operative bowel dysfunction.

PONV Product means a Product for the management of post-operative nausea or vomiting.

Field of Use
The Field means all uses of Compound in human beings except in products or formulations containing Compound and opioids.

The target audience is General Surgeons, Urologists, OB/Gyn Surgeons, Gastroenterologists, Colorectal Surgeons, Anesthesiologists, and, Abdominal Surgeons.

IPSCIO Record ID: 323765

License Grant
Licensor granted Licensee exclusive, worldwide (excluding Europe, Canada and Israel) commercialization and development rights to Movantik® (naloxegol).

The parties amended the License Agreement to grant Licensee also the exclusive commercialization and development rights to Movantik® (naloxegol) in Israel.

License Property
Movantik® (naloxegol) is a gastrointestinal drug. Movantik® works by helping to keep opioids from attaching to something called “mu-receptors” in your bowel.
Field of Use
The field of use is for the treatment of opioid-induced constipation in adults with non-cancer pain.

Opioid-induced constipation (OIC) often occurs in patients administered opioids for chronic noncancer pain. Patients commonly experience hard, infrequent, and incomplete bowel movements with bloating and straining, which may impact pain management and quality of life.  Opioid-induced constipation is attributed to activation of enteric µ-opioid receptors, which decrease bowel tone and contractility and increase colonic fluid absorption and anal sphincter tone while reducing rectal sensation. This leads to harder stools, which can be difficult to pass.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.